Doç. Dr. Dilek Erdem

• Lungenneubildungen 7 Publikationen
  Quelle: OpenAlex / PubMed MeSHPublikationen ansehen
• Brustneubildungen 6 Publikationen
• Harnblasenneubildungen 6 Publikationen
• Übergangszellkarzinom 4 Publikationen
• Nichtkleinzelliges Lungenkarzinom 4 Publikationen
• Magenneubildungen 4 Publikationen
• Kolorektale Neubildungen 3 Publikationen
• Nierenzellkarzinom 3 Publikationen
• Nierenneubildungen 3 Publikationen
• Urologische Neubildungen 2 Publikationen
• Hirnneubildungen 2 Publikationen
• COVID-19 2 Publikationen
• Neubildungen 2 Publikationen

Medizinische Interessengebiete, die der Arzt im Profil der Einrichtung selbst angegeben hat. Quelle: medicalpark.com.tr.

Berufserfahrung

• 2003 - 2008Ondokuzmayıs Üniversitesi Tıp Fakültesi Dahili Tıp Bilimleri, İç Hastalıkları Anabilim Dalı, Drmedicalpark.com.tr
• 2009 - 2009Mardin Derik Devlet Hastanesi, İç Hastalıkları, Uzmanlıkmedicalpark.com.tr
• 2009 - 2012Ondokuzmayıs Üniversitesi Tıp Fakültesi, Dahili Tıp Bilimleri, İç Hastalıkları Anabilim Dalı, Tıbbi Onkoloji Bilim Dalımedicalpark.com.tr
• 2012 - 2014Samsun Eğitim ve Araştırma Hastanesi, Tıbbi Onkoloji, Yan Dal Uzmanımedicalpark.com.tr
• 2016Bahçeşehir Üniversitesi Tıp Fakültesi İç Hastalıkları Anabilim Dalı, Tıbbi Onkoloji Bilim Dalı; Yrd Doç Drmedicalpark.com.tr

Ausbildung

• 19952001: Ondokuzmayıs Üniversitesi Tıp Fakültesi-Lisansmedicalpark.com.tr
• 20032008: Ondokuzmayıs Üniversitesi Tıp Fakültesi Dahili Tıp Bilimleri, İç Hastalıkları Anabilim Dalımedicalpark.com.tr
• 20092012: Ondokuzmayıs Üniversitesi Tıp Fakültesi, Tıbbi Onkoloji Bilim Dalı, Yandal Uzmanlıkmedicalpark.com.tr

• FachgebietMedizinische Onkologiemedicalpark.com.trAus der Quelle
• Abteilungsname in der QuelleMedikal Onkoloji (Tıbbi Onkoloji)medicalpark.com.trAus der Quelle
• EinrichtungMedical Park Samsunmedicalpark.com.trAus der Quelle
• ArbeitsschwerpunktLungenneubildungenAus 7 Publikationen ermittelt · Modellversion —Aus der Quelle
• Publikationen90 PublikationenOpenAlex, Europe PMCAus der Quelle
• ORCID0000-0001-6495-6712ORCIDAus der Quelle
• Letzte Synchronisierung4. November 2026 20:32https://www.medicalpark.com.tr/hekimler/dilek-erdemmedicalpark.com.tr

1. Prognostic factors in avelumab maintenance therapy for metastatic urothelial carcinoma

   Immunotherapy, 2026

   DOI 10.1080/1750743x.2026.2722548 PMID 42683510 Frei zugänglicher VolltextQuelle: OpenAlex

2. Abstract PS5-02-08: Impact of Prior T-DM1 Exposure on the Efficacy of Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer

   Clinical Cancer Research, 2026

   DOI 10.1158/1557-3265.sabcs25-ps5-02-08 Quelle: OpenAlex

3. Abstract PS5-05-14: Real-world outcomes of trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study

   Clinical Cancer Research, 2026

   DOI 10.1158/1557-3265.sabcs25-ps5-05-14 Quelle: OpenAlex

4. Lung Metastatic Ameloblastoma: A Hidden Cause of Pulmonary Nodules

   Balkan medical journal, 2026

   DOI 10.4274/balkanmedj.galenos.2025.2025-8-6 PMID 40936298 Frei zugänglicher VolltextQuelle: Europe PMC

5. Abstract PS4-04-11: Statins enhance trastuzumab deruxtecan efficacy: Preclinical synergy in HER2-negative models and clinical benefit in HER2-positive metastatic breast cancer

   Clinical Cancer Research, 2026

   DOI 10.1158/1557-3265.sabcs25-ps4-04-11 Quelle: OpenAlex

6. First-in-class HIF-2α therapy in genitourinary oncology: Belzutifan from von Hippel–Lindau disease to advanced renal cell carcinoma

   Cancer Chemotherapy and Pharmacology, 2026

   DOI 10.1007/s00280-025-04861-x PMID 41569310 2 Zitationen (OpenAlex) Quelle: OpenAlex

7. Efficacy and toxicity outcomes of total neoadjuvant FLOT versus perioperative FLOT in resectable gastric cancer: Results from the Turkish Oncology Gastrointestinal Cancer Working Group.

   Journal of Clinical Oncology, 2026

   DOI 10.1200/jco.2026.44.2_suppl.414 Quelle: OpenAlex

8. Clinical outcomes of adjuvant treatment strategies in locally advanced gastroesophageal and gastric adenocarcinoma with poor pathological response to neoadjuvant FLOT: A Turkish Oncology Group (TOG) study.

   Journal of Clinical Oncology, 2026

   DOI 10.1200/jco.2026.44.16_suppl.e16150 Frei zugänglicher VolltextQuelle: OpenAlex

9. Real‐world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple‐negative breast cancer: A multicenter study by the Turkish Oncology Group

   International Journal of Cancer, 2025

   DOI 10.1002/ijc.70213 PMID 41147655 3 Zitationen (Europe PMC) Quelle: OpenAlex

10. Avelumab maintenance in patients with metastatic urothelial carcinoma in a real-life expanded-access program

    Future Oncology, 2025

    DOI 10.1080/14796694.2025.2570637 PMID 41103123 Frei zugänglicher VolltextQuelle: OpenAlex